An observational study in Burn and Traumatic Implants, sponsored by Tang-Du Hospital. Status unknown at 1 site in China. Open to participants aged 3 Years to 52 Years. Per ClinicalTrials.gov, last updated 2013-04-19.
Sponsored by Tang-Du Hospital · Observational
The present study was to retrospectively evaluate the long-term outcomes of the cograft acellular dermal matrix (ADM) with autologous thin split-thickness skin for coverage of functional regional wounds in burned patients.
The potential of acellular dermal matrix (ADM) had been proved to improve cosmetic and functional outcomes, nevertheless, there had been few reports about the long term results of the morphological, histological and functional changes after placement. The present study was to retrospectively evaluate the long-term outcomes of the cograft acellular dermal matrix (ADM) with autologous thin split-thickness skin for coverage of functional regional wounds in burned patients.
719 studies on the registry are indexed under Burns; 145 are open to participants now.
This study's enrollment of 30 is below the median of 55 across 135 observational studies indexed under Burns.
Browse Burns studies →Tang-Du Hospital is the lead sponsor of 164 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Thirty burn patients, treated by composite graft of ADM with autologous split-thickness skin from January 2007 to December 2009, were enrolled in this study.
Exclusion Criteria:
Function of the region covered by human acellular dermal matrix allograft
Time frame: March, 2012 to May, 2013
Physical characteristics of the transplanted human acellular dermal matrix allograft
Time frame: March, 2012 to May, 2013
This study is status unknown, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tang-Du Hospital